1 recruiting, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow Immunocompromised: new trials by email Literature Review of Immunocompromised trials Research Report on Immunocompromised
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults casirivimab+imdevimab, Placebo - Immunocompromised | Phase 3 | Terminated | Regeneron Pharmaceuticals | 66 | 2021-10-25 | 2025-10-20 |
| Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study DAS181, Placebo, DAS181 COVID-19 - Lower Respiratory Tract Infection, Parainfluenza | Phase 3 | Recruiting | Ansun Biopharma, Inc. | 274 | 2019-05-23 | 2026-06-23 |
COVID-19 (2) · Coronavirus Infections (1) · Paramyxoviridae Infections (1)
Coronaviridae Infections (2) · Infections (2) · Lung Diseases (2) · Nidovirales Infections (2) · Pneumonia (2) · Pneumonia, Viral (2) · RNA Virus Infections (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Virus Diseases (2) · Coronavirus Infections (1) · Mononegavirales Infections (1)
casirivimab (1) · casirivimab and imdevimab drug combination (1) · imdevimab (1) · oplunofusp (1)
Ansun Biopharma, Inc. (1) · Regeneron Pharmaceuticals (1)
United States (2) · Australia (1) · China (1) · Mexico (1) · South Korea (1) · Taiwan (1)
2018 (1)